Bethanie Wilkinson

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 922 citations · Full text

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine · 2014 · 761 citations · Full text

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 541 citations

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese et al. · Arthritis & Rheumatism · 2011 · 376 citations